Propanc Biopharma, Inc. Common Stock (PPCB) — Cash Flow-to-Debt Ratio
Propanc Biopharma, Inc. Common Stock (PPCB) has a Cash Flow-to-Debt Ratio of -0.21x as of December 2025, meaning its operating cash flow of $-999.14K could theoretically repay 0% of its total liabilities ($4.66 Million) in one year. See working capital to net assets of Propanc Biopharma, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Propanc Biopharma, Inc. Common Stock Cash Flow-to-Debt Ratio (2010–2025)
Historical debt coverage capacity for Propanc Biopharma, Inc. Common Stock across 16 annual periods. Also explore Propanc Biopharma, Inc. Common Stock (PPCB) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Propanc Biopharma, Inc. Common Stock (2010–2025)
Year-by-year debt coverage analysis for Propanc Biopharma, Inc. Common Stock. For market capitalisation and broader financial context, see market value of Propanc Biopharma, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-405.17K | $5.73 Million | ▲ +70.9% |
| 2024 | -0.24x | $-935.12K | $3.85 Million | ▲ +30.2% |
| 2023 | -0.35x | $-1.11 Million | $3.18 Million | ▲ +24.8% |
| 2022 | -0.46x | $-1.44 Million | $3.11 Million | ▼ -24.4% |
| 2021 | -0.37x | $-1.15 Million | $3.08 Million | ▲ +24.8% |
| 2020 | -0.49x | $-1.85 Million | $3.74 Million | ▼ -5.7% |
| 2019 | -0.47x | $-2.06 Million | $4.40 Million | ▼ -46.6% |
| 2018 | -0.32x | $-2.18 Million | $6.82 Million | ▲ +17.9% |
| 2017 | -0.39x | $-2.15 Million | $5.54 Million | ▲ +76.2% |
| 2016 | -1.63x | $-4.80 Million | $2.94 Million | ▼ -320.6% |
| 2015 | -0.39x | $-1.43 Million | $3.68 Million | ▼ -160.5% |
| 2014 | -0.15x | $-226.44K | $1.52 Million | ▲ +8.2% |
| 2013 | -0.16x | $-128.65K | $794.22K | ▲ +44.4% |
| 2012 | -0.29x | $-170.28K | $584.19K | ▲ +93.6% |
| 2011 | -4.55x | $-1.40 Million | $306.85K | ▼ -448.0% |
| 2010 | -0.83x | $-191.51K | $230.76K | — |